ClinicalTrials.gg
RecruitingNCT07230353Updated Aug 3, 2026

A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid Arthritis

A Phase 1 interventional study of Plamotamab in Rheumatoid Arthritis, sponsored by Xencor, Inc.. Recruiting at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by Xencor, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
68
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies in Arthritis, Rheumatoid with a site in Georgia — 6 open to participants now, 10 under way, none of them phase 3. Arthritis, Rheumatoid · Georgia.

Planned enrollment
27th of 34
68 · median 135
Started
2025
with 5 others
Phase 1
8 of 34
5 open now
Registered
31st of 34
by date

Among the 34 studies in Arthritis, Rheumatoid with a site in Georgia, this one is the 27th largest by planned enrollment, is one of 6 that started in 2025, is one of 8 in phase 1, and was the 31st registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

6 of the 34 studies in Arthritis, Rheumatoid with a site in Georgia are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Georgia have not opened yet or have stopped. Only those recruiting at a site in Georgia →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Arthritis, Rheumatoid with a site in Georgia, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety and tolerability of plamotamab in patients with rheumatoid arthritis. Participants will be given XmAb13676 subcutaneously (SC) by injection under the skin.

Read the detailed description

This is a Phase 1b study to determine the safety, tolerability, pharmacokinetic (PK), and pharmacodynamics (PD), and immunogenicity of plamotamab in adult participants with moderately to severely active RA. This is an open label dose optimization trial with approximately 68 participants assigned to different dose escalation cohorts.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatoid Arthritis, Arthritis Rheumatoid, Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Adult participants with moderately to severely active RA.

  • Documented diagnosis of RA and meeting the 2010 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for RA at least 3 months prior to screening
  • Inadequate response to, loss of response to, or intolerance to available RA therapies.
  • Stable doses of RA medications prior to screening
  • Use of highly effective methods of

Exclusion Criteria:

  • Major surgery within 12 weeks prior to screening or planned within 12 months after dosing
  • Recurrent infections or active infection
  • Active or untreated latent tuberculosis
  • Cancer or history of cancer or lymphoproliferative disease within the previous 5 years
  • Uncontrolled cardiovascular, pulmonary, renal, hepatic, endocrine, or gastrointestinal disease

Note: Additional, more specific inclusion/exclusion criteria are defined in the protocol.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
68 participants (estimated)

Study arms

  • Experimental
    Dose Escalation

    Plamotamab administered SC

    Biological: Plamotamab

Interventions

06

What researchers measure

Primary outcomes

  1. Primary

    Percentage of participants with treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)

    Time frame: Through Week 52

Secondary outcomes

  1. Secondary

    Serum concentration of plamotamab

    Time frame: Through Week 52

07

Study locations

3 of 3 sites recruiting
  • Xencor Investigative Site
    Tbilisi, Georgia
    Recruiting
  • Xencor Investigative Site
    Chisinau, Moldova
    Recruiting
  • Xencor Investigative Site
    Auckland, New Zealand
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Jun 2028, 32 months after the start.

Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's planned 32 months is above that.

Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2025
First posted
Nov 17, 2025
StartActual
Oct 21, 2025
Primary completionEst.
Jun 2028
CompletionEst.
Jun 2028
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07230353
Lead sponsor
Xencor, Inc.
Responsible party
Sponsor
First posted
Nov 17, 2025
Start date
Oct 21, 2025
Primary completion
Jun 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Aug 3, 2026

Study contacts

676-06 Study Information
Contact
676-Aiinfo@xencor.com
676-06 Study Information
study director · Xencor, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Plamotamab

Start the discussion